Advances in Locally Advanced and Metastatic Kidney Cancer (2nd Edition)

Dear Colleagues,

This Special Issue is the second edition of a previous issue on the topic of “Advances in Locally Advanced and Metastatic Kidney Cancer”.

Our biological understanding and clinical management of kidney cancer has advanced significantly in recent years. In particular, the introduction of novel immune checkpoint inhibitors has led to unprecedented responses in metastatic disease and improved patient survival. These developments have paved the way for the emergence of rational, synergistic combinations of immunotherapies and targeted therapies.

Advanced renal cell carcinoma (RCC) exhibits a wide clinical spectrum, ranging from non-metastatic, high-risk or locally advanced tumors, to oligometastatic disease, to more widely disseminated metastatic involvement. In the locally advanced setting, there is increasing interest in administering systemic therapies in the perioperative (neoadjuvant or adjuvant) setting to reduce recurrence. In the study of oligometastatic disease, new approaches to the locoregional management of metastatic sites, such as stereotactic radiation, have been employed to delay or obviate the need for systemic therapy while minimizing morbidity. In more widely disseminated disease, novel therapeutic agents and rational combinations continue to emerge for both clear cell and non-clear cell RCC histologies. The role and timing for cytoreductive nephrectomy in metastatic disease continue to evolve, and the optimal setting remains uncertain. Furthermore, diagnostic, prognostic, and predictive circulating biomarkers remain an active area of research interest across the spectrum of RCC, while advances in diagnostic imaging are contributing to both improved diagnosis and potential theranostic applications.

In this Special Issue, we are seeking high-quality, original work that highlights advances in locally advanced and metastatic kidney cancer, pertaining to the themes outlined above. We look forward to receiving your contributions.

Dr. Nirmish Singla
Dr. Yasser Ged
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.